FMS NYSE Week ended 31 Jul 2026

Weekly Investor Report

Fresenius Medical Care Corporation · Healthcare · Medical Care Facilities

Open interactive chart View report data
Latest close 25.66 USD
4.4% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 14.2% above the Trend Line and sits at 87.6% of its 52-week range. The latest completed week returned 4.4%, after a 9.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers. Options positioning is mixed with 33/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 3d.

Setup score 58 out of 100
Latest Close 25.66 USD 31 Jul 2026
1W Return 4.4% latest completed week
4W Return 9.1% short-term follow-through
12W Return 21.2% quarterly tape
Trend Breadth 11.5% 6 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.4% Latest completed week; four-week move 9.1%. Indicator stack 24/73 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 33/100 conviction; expected move 6.3%. News sentiment 55/100 63 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.2% above the Trend Line and sits at 87.6% of its 52-week range. The latest completed week returned 4.4%, after a 9.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6312-week average 0.29

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.63Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 9.1% over four weeks, 21.2% over 12 weeks, and 6.2% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W4.4%
4W9.1%
12W21.2%
26W17.6%
52W6.2%
Active trend streak5 weeks
Active weeks in one year6
Trend breadth11.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.29Latest activity-pressure read.
Pressure change-4.5%Four-week change in activity pressure.
Leadership1.85Latest relative-leadership reading.
RS change123.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength85/100Blend of value, momentum, and quality. Underlying universe rank 16; rank 1 is best.
Value92/100Relative valuation strength. Underlying universe rank 9; rank 1 is best.
Quality72/100Profitability and accounting quality. Underlying universe rank 29; rank 1 is best.
Momentum24/100Medium-term price momentum. Underlying universe rank 77; rank 1 is best.
Growth23/100Revenue and earnings growth. Underlying universe rank 78; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework68/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
14.0x
Price divided by trailing earnings.
Price / sales
0.7x
Market value relative to trailing revenue.
EV / EBITDA
7.0x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
15.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
26.0%
Gross profit retained from each unit of revenue.
Operating margin
9.6%
Operating profit retained from revenue.
Free-cash-flow margin
18.9%
Free cash flow generated from revenue.
Return on invested capital
6.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-0.7%
Latest one-year revenue growth.
EPS growth
52.8%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
17.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.5%
Cash dividends relative to market value.
Buyback yield
4.4%
Net share repurchases relative to market value.
Shareholder yield
8.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

FMS shows mixed options pressure with a 33/100 conviction score, put-call volume ratio of n/a, expected move of 6.3%, and Sharemaestro trend signal active.

Conviction33/100
Expected move6.3%
Put/call volume
Pressure-8
Speculation0
Volatility44
Trend agreement99
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 63 relevant articles.

24 positive · 33 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move6.3%Nearest-chain priced movement where available.
52-week drawdown-3.4%Distance below the 52-week high.
13-week volatility2.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+6.1%Week of 6 Feb.
Worst week-5.0%Week of 20 Mar.
Latest week+4.4%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains9
Flat weeks0
Modest losses11
Sharp losses1
Recent vol2.2%13-week weekly-return volatility.
Base vol3.0%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew2.2% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape52/100

Trend, activity pressure, participation, and risk combine to a 52/100 tape read.

 Indicator analysis46/100

Latest 12-week confirmation: trend 5/12, activity pressure 8/12, relative leadership 1/12.

Activity pressure 0.63; No reversal markers Factors69/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 13; Small Cap Core rank 6 SVQF68/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 320.0 of 1013 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options59/100

FMS shows mixed options pressure with a 33/100 conviction score, put-call volume ratio of n/a, expected move of 6.3%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 6.3% Sentiment55/100

Weighted news tone is neutral across 63 relevant articles.

Fresenius Medical Care stock trades steadily as dialysis margins and turnaround plan shape investor focus Insiders50/100

No recent insider transaction evidence is stored.

 Earnings3d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202625.66 USD4.4%22.47 USD21.34 USD1.291.853.6MOn
24 Jul 202624.59 USD2.0%22.37 USD21.32 USD1.27-1.612.6MOn
17 Jul 202624.11 USD0.4%22.32 USD21.32 USD1.28-4.482.9MOn
10 Jul 202624.02 USD2.1%22.27 USD21.32 USD1.33-6.762.2MOn
3 Jul 202623.53 USD1.2%22.23 USD21.32 USD1.35-7.953.8MOn
26 Jun 202623.24 USD-1.5%22.19 USD21.31 USD1.20-7.742.8MOff
19 Jun 202623.59 USD2.5%22.18 USD21.30 USD0.89-9.222.2MOff
12 Jun 202623.02 USD4.5%22.14 USD21.29 USD0.46-11.192.6MOff
5 Jun 202622.03 USD2.1%22.12 USD21.28 USD-0.01-15.255.3MOff
29 May 202621.57 USD-0.3%22.16 USD21.27 USD-0.19-19.824.8MOff
22 May 202621.64 USD4.2%22.30 USD21.26 USD-0.21-19.193.0MOff
15 May 202620.76 USD-2.0%22.45 USD21.25 USD-0.06-22.605.0MOff
8 May 202621.18 USD-2.0%22.63 USD21.25 USD0.24-21.636.9MOff
1 May 202621.62 USD-1.2%22.78 USD21.25 USD0.25-18.912.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.